Cometriq: new protein kinase inhibitor for thyroid carcinoma

Cometriq (cabozantinib) is indicated for the treatment of adults with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Medullary thyroid cancer is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. SCIENCE PHOTO LIBRARY
Medullary thyroid cancer is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. SCIENCE PHOTO LIBRARY

Cabozantinib inhibits the activity of tyrosine kinases (including RET, MET and VEGF receptors) involved in cellular function and pathologic processes such as oncogenesis, metastasis, tumour angiogenesis and maintenance of the tumour microenvironment.

Survival benefit

The safety and efficacy of cabozantinib were established in a randomised, double-blind trial involving 330 patients with unresectable locally advanced or metastatic medullary thyroid cancer who had radiographic evidence of disease progression within 14 months before study entry.

Patients who received cabozantinib 140mg once daily survived for a median of 11.2 months without tumour progression compared with a median of 4 months in the placebo group (HR 0.28, 95% CI 0.19-0.40, p<0.001). Prior therapy with tyrosine kinase inhibitors had no influence on progression-free survival rates.

The overall response rate in cabozantinib-treated patients was 28%, compared with 0% in those who received placebo (p<0.0001). Estimated responses lasted a median of 14.6 months in the cabozantinib arm (95% CI 11.1-17.5 months).

Safety

The most commonly reported serious adverse reactions of cabozantinib were pneumonia, mucosal inflammation, hypocalcaemia, dysphagia, dehydration, pulmonary embolism and hypertension.

View Cometriq drug record

Further information: Swedish Orphan Biovitrum


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.